Although the 5-year survival rate for multiple myeloma is less than 50%, this type of cancer has witnessed a resurgence of drug therapies.

The Oncology Pharmacist (TOP) spoke with Steve Stricker, PharmD, MS, BCOP at the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference about the importance of provider status, why clinical oncologists may be overlooked by their peers, and the most fulfilling part of his work.

Childhood cancer therapy can be a double-edged sword; it often leads to a cure, but long after treatment ends, some survivors have treatment-related side effects.